Mutations in key regulatory genes, such as KRAS, TP53, and BRCA1/2, drive PDAC progression, while the tumor immune microenvironment, characterized by immunosuppressive stromal features and variable immune cell infiltration, further modulates patient outcomes. The gene discussed is TP53; the disease is neoplasm.